Pharvaris N.V. (PHVS)

$35.14 +1.10 (3.23%)
Market Cap 2.30B
Revenue (ttm) 0.00
Net Income (ttm) -198.79M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 862,900
Avg Vol 492,190
Day's Range N/A - N/A
Shares Out 65.41M
Stochastic %K 59%
Beta -2.31
Analysts Strong Sell
Price Target $49.31

Company Profile

Pharvaris N.V., a late-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs covering angioedema and other bradykinin-mediated diseases. The company develops deucrictibant, a small molecule bradykinin B2-receptor antagonist to treat attacks due to bradykinin-mediated angioedema, including hereditary angioedema (HAE) and acquired angioedema due to C1-inhibitor deficiency (AAE-C1INH), which is in phase 3, as well as in pha...

Industry: Biotechnology
Sector: Healthcare
Phone: 31 712036410
Address:
Grafenauweg 8, Zug, Switzerland
JuggernautRaider
JuggernautRaider Aug. 17 at 10:56 AM
$PHAR needs a lot of help. Big Wim at Pharvarid $PHVS is about to eat their HAE lunch like Kalvista did before they got bounced. Pharming Group of NJ? It is a mess! I may help them. I may not. I have a couple of friends there… maybe if they ask niiiicely 😜 Maybe $AXSM should buy something like Tonix after all. NJ is a MESS! GO $JNJ GO! FIX AMERICAAAAAAAN HEALTHCARE 🇺🇸 🧪 🤖
0 · Reply
CH_Expat
CH_Expat Aug. 17 at 8:19 AM
$PHVS You might hate me for this, but pay attention here before the readout. I think stellar results might already be priced in. The Baker Bros sold what they had in Q2.
0 · Reply
Quantumup
Quantumup Aug. 13 at 5:07 PM
$PHVS Guggenheim⬆️to $40 vs $39; stays Buy BofA⬆️to $38 vs $35; stays Neutral RBC Capital⬆️to $52 vs $51; stays OP $KALV $BCRX IONS TAK Citizens⬆️to $75 vs $74; stays Outperform and said -- Positive Phase 3 CHAPTER-3 data could drive shares materially higher, with deucrictibant showing strong efficacy, significant U.S. adoption potential, roughly $2.5B sales potential if Phase 2 results are replicated, and peak global sales modeled around $1B for HAE attacks plus about $1.2B in U.S. prophylaxis sales. Here's what Citizens went on to say: https://x.com/Quantumup1/status/2087948836790509923?s=20
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 13 at 1:33 PM
$PHAT $PHVS $PHAR are STRUGGLING! $ALT … of Morristown? Under CEO Jerry Durso? They are tightening up! ⬆️ 💪 🏃‍♂️ Back to school, children 👧
0 · Reply
G101SPM
G101SPM Aug. 12 at 5:56 PM
#OPTIONACTION $HPE Sep 70.0 calls (volume: 1.5K, open int: 0, implied vol: ~78%, prev day implied vol: 66%). Underlying stock is trading higher by 4%. Co is expected to report earnings early-September. $NUAI Aug 6.0 calls (volume: 11.1K, open int: 2.1K, implied vol: ~167%, prev day implied vol: 134%). Underlying stock is trading higher by 6%. $NN Dec 26.0 calls (volume: 5.0K, open int: 0, implied vol: ~106%, prev day implied vol: 84%). Underlying stock is trading higher by 4%. $PHVS Oct 17.5 puts (volume: 5.0K, open int: 0, implied vol: ~102%, prev day implied vol: 64%). Pharvaris reported second quarter 2026 financial results and provided business updates. $HPQ Aug 31.0 puts (volume: 4.0K, open int: 4.0K, implied vol: ~57%, prev day implied vol: 52%). Co is confirmed to report earnings, August 26, after market close.
0 · Reply
Lady_M
Lady_M Aug. 3 at 7:04 AM
$PHVS Bullish
0 · Reply
Merlintrader
Merlintrader Aug. 2 at 3:38 PM
The Top Ten Biotech Stocks Right Now — updated for August with upcoming catalysts, clinical readouts, cash runway and key risks. Four names in focus: $RARE $PHVS $SLS $TLX Full ranked watchlist: https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
1 · Reply
Merlintrader
Merlintrader Jul. 25 at 9:07 PM
$RARE $TENX $CAPR $PHVS The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
0 · Reply
Merlintrader
Merlintrader Jul. 25 at 6:38 PM
$PHVS Pharvaris ($PHVS) Stock Hub: Deucrictibant, CHAPTER-3 and the HAE Franchise Thesis https://www.merlintrader.com/pharvaris-stock-hub/
0 · Reply
fda_tracker
fda_tracker Jul. 24 at 2:30 PM
$PHVS Phase 3 trial w/est Jul completion date NCT05834777: https://www.clinicaltrials.gov/study/NCT05834777 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Latest News on PHVS
Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year

2026-08-17T10:02:03.000Z - 3 hours ago

Pharvaris reports Q2 EPS (EUR 0.70) vs. (EUR 0.83) last year

Pharvaris price target raised to $75 from $74 at Citizens

2026-08-17T08:29:14.000Z - 5 hours ago

Pharvaris price target raised to $75 from $74 at Citizens

Pharvaris price target raised to $38 from $35 at BofA

2026-08-17T08:17:41.000Z - 5 hours ago

Pharvaris price target raised to $38 from $35 at BofA

Pharvaris price target raised to $40 from $39 at Guggenheim

2026-08-17T08:10:37.000Z - 5 hours ago

Pharvaris price target raised to $40 from $39 at Guggenheim

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Aug 12, 2026, 6:50 AM EDT - 5 days ago

Pharvaris Reports Second Quarter 2026 Financial Results and Provides Business Update

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Aug 6, 2026, 6:50 AM EDT - 11 days ago

Assessment of AAE-C1INH Disease Burden and Validation of Clinical Trial Endpoints Published in Frontiers in Immunology

Pharvaris price target raised to $35 from $33 at BofA

2026-07-29T13:15:51.000Z - 19 days ago

Pharvaris price target raised to $35 from $33 at BofA

Pharvaris announces publication of review article on bradykinin

2026-07-22T10:55:33.000Z - 26 days ago

Pharvaris announces publication of review article on bradykinin

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Jul 22, 2026, 6:50 AM EDT - 26 days ago

Publication in Clinical Reviews in Allergy & Immunology Summarizes Decades of Evidence Supporting Bradykinin B2 Receptor as a Validated Therapeutic Target in Bradykinin-Mediated Angioedema

Pharvaris initiated with an Overweight at Wells Fargo

2026-07-15T09:35:23.000Z - 4 weeks ago

Pharvaris initiated with an Overweight at Wells Fargo

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Jul 6, 2026, 6:50 AM EDT - 6 weeks ago

Pharvaris Announces FDA Acceptance of New Drug Application for Deucrictibant IR for On-Demand Treatment of Hereditary Angioedema Attacks

Pharvaris price target raised to $46 from $41 at Morgan Stanley

2026-06-25T10:50:28.000Z - 7 weeks ago

Pharvaris price target raised to $46 from $41 at Morgan Stanley

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Jun 15, 2026, 6:50 AM EDT - 2 months ago

Data Supporting Differentiated Profile of Deucrictibant in HAE Management Presented at EAACI 2026

Pharvaris Announces Annual General Meeting of Shareholders

Jun 11, 2026, 6:50 AM EDT - 2 months ago

Pharvaris Announces Annual General Meeting of Shareholders

HAE

Pharvaris management to meet with Oppenheimer

2026-06-03T19:50:45.000Z - 2 months ago

Pharvaris management to meet with Oppenheimer

Pharvaris management to meet with Oppenheimer

2026-05-29T20:40:52.000Z - 2 months ago

Pharvaris management to meet with Oppenheimer

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

May 29, 2026, 6:50 AM EDT - 2 months ago

Pharvaris to Present Clinical Data at the EAACI Annual Congress 2026

Pharvaris Transcript: RBC Capital Markets Global Healthcare Conference 2026

May 20, 2026, 11:00 AM EDT - 3 months ago

Pharvaris Transcript: RBC Capital Markets Global Healthcare Conference 2026

Pharvaris price target raised to $33 from $31 at BofA

2026-05-14T19:43:32.000Z - 3 months ago

Pharvaris price target raised to $33 from $31 at BofA

Pharvaris Transcript: Bank of America Global Healthcare Conference 2026

May 13, 2026, 11:40 AM EDT - 3 months ago

Pharvaris Transcript: Bank of America Global Healthcare Conference 2026

Pharvaris price target lowered to $74 from $75 at Citizens

2026-05-13T09:55:47.000Z - 3 months ago

Pharvaris price target lowered to $74 from $75 at Citizens

Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year

2026-05-12T21:21:54.000Z - 3 months ago

Pharvaris reports Q1 EPS (EUR 0.59) vs. (EUR 0.85) last year

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

May 12, 2026, 4:05 PM EDT - 3 months ago

Pharvaris Reports First Quarter 2026 Financial Results and Provides Business Update

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

May 11, 2026, 4:15 PM EDT - 3 months ago

Pharvaris Announces Closing of $132.3 Million Underwritten Offering of Ordinary Shares and Full Exercise of Underwriters' Option to Purchase Additional Shares

Pharvaris price target raised to $31 from $30 at BofA

2026-05-10T14:35:05.000Z - 3 months ago

Pharvaris price target raised to $31 from $30 at BofA

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

May 8, 2026, 6:00 AM EDT - 3 months ago

Pharvaris Announces Pricing of $115 Million Underwritten Offering of Ordinary Shares

Pharvaris presents data from deucrictibant IR capsule and XR tablet study

2026-04-20T11:04:50.000Z - 4 months ago

Pharvaris presents data from deucrictibant IR capsule and XR tablet study

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Apr 20, 2026, 6:50 AM EDT - 4 months ago

Evidence Supporting Combined Use of Deucrictibant IR with Deucrictibant XR Presented at CIIC Spring 2026 Conference

Pharvaris price target raised to $52 from $48 at JonesResearch

2026-04-15T19:40:56.000Z - 4 months ago

Pharvaris price target raised to $52 from $48 at JonesResearch

Pharvaris initiated with an Outperform at Wolfe Research

2026-04-08T20:40:13.000Z - 4 months ago

Pharvaris initiated with an Outperform at Wolfe Research

Pharvaris price target raised to $42 from $41 at Wedbush

2026-04-07T11:47:27.000Z - 4 months ago

Pharvaris price target raised to $42 from $41 at Wedbush

Pharvaris price target lowered to $51 from $52 at RBC Capital

2026-04-06T12:46:24.000Z - 4 months ago

Pharvaris price target lowered to $51 from $52 at RBC Capital

Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year

2026-04-02T11:25:00.000Z - 4 months ago

Pharvaris reports Q4 EPS (EUR 0.72) vs. (EUR 0.64) last year

Pharvaris Annual report: Q4 2025

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Pharvaris Annual report: Q4 2025

Pharvaris Earnings release: Q4 2025

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Pharvaris Earnings release: Q4 2025

Pharvaris Annual report: Q4 2025

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Pharvaris Annual report: Q4 2025

Pharvaris Slides: Corporate presentation

Apr 2, 2026, 7:00 AM EDT - 4 months ago

Pharvaris Slides: Corporate presentation

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Apr 2, 2026, 6:50 AM EDT - 4 months ago

Pharvaris Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

Pharvaris announces publications of efficacy, safety evidence on deucrictibant

2026-03-20T10:55:34.000Z - 5 months ago

Pharvaris announces publications of efficacy, safety evidence on deucrictibant

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

Mar 20, 2026, 6:50 AM EDT - 5 months ago

Evidence of Efficacy and Safety of Deucrictibant for Prophylaxis and On-Demand Treatment of Hereditary Angioedema Attacks Published Back-to-Back in The Lancet Haematology

Pharvaris Transcript: Leerink Global Healthcare Conference 2026

Mar 11, 2026, 9:20 AM EDT - 5 months ago

Pharvaris Transcript: Leerink Global Healthcare Conference 2026

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Mar 11, 2026, 6:50 AM EDT - 5 months ago

Validation of Patient-Reported Outcomes in the On-Demand Treatment of Hereditary Angioedema Attacks Published in Clinical Reviews in Allergy & Immunology

Pharvaris Transcript: The Citizens Life Sciences Conference 2026

Mar 10, 2026, 11:20 AM EDT - 5 months ago

Pharvaris Transcript: The Citizens Life Sciences Conference 2026

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

Mar 2, 2026, 6:50 AM EST - 6 months ago

Deucrictibant Data Supporting Potentially Differentiated Profile for the On-Demand and Prophylactic Treatment of Bradykinin-Mediated Angioedema Presented at AAAAI 2026

Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Feb 26, 2026, 9:20 AM EST - 6 months ago

Pharvaris Transcript: Oppenheimer 36th Annual Healthcare Life Sciences Conference

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Feb 10, 2026, 6:50 AM EST - 6 months ago

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris Outlines 2026 Strategic Priorities

Jan 12, 2026, 6:50 AM EST - 7 months ago

Pharvaris Outlines 2026 Strategic Priorities

Pharvaris Transcript: Study Update

Dec 3, 2025, 8:00 AM EST - 9 months ago

Pharvaris Transcript: Study Update

Pharvaris Press release: Study Update

Dec 3, 2025, 8:00 AM EST - 9 months ago

Pharvaris Press release: Study Update

Pharvaris Slides: Study Update

Dec 3, 2025, 8:00 AM EST - 9 months ago

Pharvaris Slides: Study Update

JuggernautRaider
JuggernautRaider Aug. 17 at 10:56 AM
$PHAR needs a lot of help. Big Wim at Pharvarid $PHVS is about to eat their HAE lunch like Kalvista did before they got bounced. Pharming Group of NJ? It is a mess! I may help them. I may not. I have a couple of friends there… maybe if they ask niiiicely 😜 Maybe $AXSM should buy something like Tonix after all. NJ is a MESS! GO $JNJ GO! FIX AMERICAAAAAAAN HEALTHCARE 🇺🇸 🧪 🤖
0 · Reply
CH_Expat
CH_Expat Aug. 17 at 8:19 AM
$PHVS You might hate me for this, but pay attention here before the readout. I think stellar results might already be priced in. The Baker Bros sold what they had in Q2.
0 · Reply
Quantumup
Quantumup Aug. 13 at 5:07 PM
$PHVS Guggenheim⬆️to $40 vs $39; stays Buy BofA⬆️to $38 vs $35; stays Neutral RBC Capital⬆️to $52 vs $51; stays OP $KALV $BCRX IONS TAK Citizens⬆️to $75 vs $74; stays Outperform and said -- Positive Phase 3 CHAPTER-3 data could drive shares materially higher, with deucrictibant showing strong efficacy, significant U.S. adoption potential, roughly $2.5B sales potential if Phase 2 results are replicated, and peak global sales modeled around $1B for HAE attacks plus about $1.2B in U.S. prophylaxis sales. Here's what Citizens went on to say: https://x.com/Quantumup1/status/2087948836790509923?s=20
0 · Reply
JuggernautRaider
JuggernautRaider Aug. 13 at 1:33 PM
$PHAT $PHVS $PHAR are STRUGGLING! $ALT … of Morristown? Under CEO Jerry Durso? They are tightening up! ⬆️ 💪 🏃‍♂️ Back to school, children 👧
0 · Reply
G101SPM
G101SPM Aug. 12 at 5:56 PM
#OPTIONACTION $HPE Sep 70.0 calls (volume: 1.5K, open int: 0, implied vol: ~78%, prev day implied vol: 66%). Underlying stock is trading higher by 4%. Co is expected to report earnings early-September. $NUAI Aug 6.0 calls (volume: 11.1K, open int: 2.1K, implied vol: ~167%, prev day implied vol: 134%). Underlying stock is trading higher by 6%. $NN Dec 26.0 calls (volume: 5.0K, open int: 0, implied vol: ~106%, prev day implied vol: 84%). Underlying stock is trading higher by 4%. $PHVS Oct 17.5 puts (volume: 5.0K, open int: 0, implied vol: ~102%, prev day implied vol: 64%). Pharvaris reported second quarter 2026 financial results and provided business updates. $HPQ Aug 31.0 puts (volume: 4.0K, open int: 4.0K, implied vol: ~57%, prev day implied vol: 52%). Co is confirmed to report earnings, August 26, after market close.
0 · Reply
Lady_M
Lady_M Aug. 3 at 7:04 AM
$PHVS Bullish
0 · Reply
Merlintrader
Merlintrader Aug. 2 at 3:38 PM
The Top Ten Biotech Stocks Right Now — updated for August with upcoming catalysts, clinical readouts, cash runway and key risks. Four names in focus: $RARE $PHVS $SLS $TLX Full ranked watchlist: https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
1 · Reply
Merlintrader
Merlintrader Jul. 25 at 9:07 PM
$RARE $TENX $CAPR $PHVS The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
0 · Reply
Merlintrader
Merlintrader Jul. 25 at 6:38 PM
$PHVS Pharvaris ($PHVS) Stock Hub: Deucrictibant, CHAPTER-3 and the HAE Franchise Thesis https://www.merlintrader.com/pharvaris-stock-hub/
0 · Reply
fda_tracker
fda_tracker Jul. 24 at 2:30 PM
$PHVS Phase 3 trial w/est Jul completion date NCT05834777: https://www.clinicaltrials.gov/study/NCT05834777 Trial Tracker: https://www.fdatracker.com/trial-tracker/
0 · Reply
Merlintrader
Merlintrader Jul. 22 at 8:51 PM
$RARE $PHVS $EYPT $TENX
0 · Reply
Merlintrader
Merlintrader Jul. 21 at 8:32 PM
$RARE $PHVS $EYPT $TENX The Top Ten Biotech Stocks Right Now https://www.merlintrader.com/top-ten-biotech-stocks-right-now/
0 · Reply
biotech_curious
biotech_curious Jul. 20 at 2:06 PM
$PHVS Next catalyst will be Ph3 Prophy readout? Success would give them acute and prophylactic settings. They've already published tolerability of taking both together. One package for both scenarios may be very convenient for patients.
0 · Reply
Merlintrader
Merlintrader Jul. 12 at 10:57 PM
$SNY Sanofi, Guardant Health $GH and Pharvaris $PHVS - Biotech Radar July 13: catalysts, recent news and key risks https://www.merlintrader.com/biotech-radar-july13-2026/
0 · Reply
laaarsas
laaarsas Jul. 9 at 7:53 PM
$PHVS I guess I should have bought in here earlier... before the run-up and XBI rally started... what effect size do we need to see in ph3?
0 · Reply
laaarsas
laaarsas Jul. 9 at 4:04 PM
$PHVS What vibe like here?
0 · Reply
forprofit12
forprofit12 Jul. 8 at 5:52 PM
$PHVS added
0 · Reply
fda_tracker
fda_tracker Jul. 7 at 3:47 PM
$PHVS New PDUFA Date 2027-04-23 Pharvaris N.V. Link:https://www.globenewswire.com/news-release/2026/07/06/3322293/0/en/pharvaris-announces-fda-acceptance-of-new-drug-application-for-deucrictibant-ir-for-on-demand-treatment-of-hereditary-angioedema-attacks.html Calendar:http://www.fdatracker.com/fda-calendar/
0 · Reply
Merlintrader
Merlintrader Jul. 7 at 3:18 PM
$VANI Biotech Radar: $VANI, $PHVS, $TOVX — Three Catalyst Stories From GLP-1 Implants to HAE and Pancreatic Cancer https://www.merlintrader.com/biotech-radar-july7-deepdive/
0 · Reply
Merlintrader
Merlintrader Jul. 6 at 1:55 PM
$AGEN $PHVS, $AGEN, $IONS: three biotech stories to watch across FDA review, oncology survival data and pivotal rare-disease execution https://www.merlintrader.com/biotech-radar-phvs-agen-ions-july-2026/
0 · Reply
biotech_curious
biotech_curious Jul. 6 at 11:59 AM
$PHVS NDA Accepted. PDUFA 23APR2027 I really think people should be paying attention to this paper in regards to PHVS: https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2026.1740800/full
0 · Reply
JuggernautRaider
JuggernautRaider Jun. 22 at 7:20 PM
$ALLR buying opportunities all over 👍 $PHVS is interesting 💊 $GH too 📊 Sold my $FBIO shares to buy other things 🏦 GLBB ☘️ 🐂
1 · Reply